Sil Lutkewitte

Developing the targeted therapy, GB13, for the treatment of adult and pediatric brain cancer @targepeutics

[Sil Lutkewitte @lutkewitte]

We have updated our partners page: https://t.co/dFpye7EeDJ
Thank you to all our partners who have committed efforts to Targepeutics to advance our therapy for #DIPG #DMG. Support from this community is critical and allows us to continue moving forward.

[Sil Lutkewitte @lutkewitte]

@Targepeutics We are grateful to Penn State College of Medicine, Beat Childhood Cancer Research Coalition, Four Diamonds and all those who have brought us to the doorstep of delivering GB13 to the clinic for these kids and their families suffering from DIPG/DMG.

[Targepeutics @Targepeutics]

🚨 Big news! We’re welcoming the @YuvaanTiwari Foundation as a new strategic partner in our fight against #DIPG. Their investment advances GB13 into clinical trials. Together, we’re fighting one of the deadliest pediatric brain cancers with bold science and deep purpose.#DMG

[Targepeutics @Targepeutics]

Words can’t express the gratitude to @tough2gether and DDRFA and the continued support of our upcoming #DIPG #DMG trial with GB13. #behindtheribbon

[Targepeutics @Targepeutics]

A great @beatccorg annual meeting. Grateful to Dr Sholler, BCC and @fourdiamonds for the continued support! #DIPG #DMG

[Sil Lutkewitte @lutkewitte]

@DrAMansouri @theNCI Really happy for you and the Team! Congratulations Alireza.

[Alireza Mansouri @DrAMansouri]

@Targepeutics @GSholler @beatccorg Fantastic work @Targepeutics . Looking forward to bringing GB13 into clinical trials! #glioblastoma #DIPG #RareDiseaseDay @EndBrainCancer @ourbrainbank @NBTStweets @braintumourrsch @WeTrialshub

[Targepeutics @Targepeutics]

We want to thank Dr. Giselle Sholler @GSholler and the entire @beatccorg team for giving us this opportunity to talk about GB13, our promising lead therapeutic for #DIPG #DMG.

[Alireza Mansouri @DrAMansouri]

Grateful to the W. W. Smith Trust for funding our project, which will further strengthen our ability to leverage liquid biopsy in identifying candidates for clinical trials and for disease monitoring. Excited for our collaboration with @Targepeutics. @PennStateNSGY #Glioblastoma

[Targepeutics @Targepeutics]

Excited to have our collaborative research on GB13 as a #DMG treatment shared by Julian Rechberger #SNOPeds #DIPG

[Sil Lutkewitte @lutkewitte]

IL13Ra2 is overexpressed on brain cancer; we have drugs that target the receptor and are ready NOW, but no $ to finish. HELP #CancerMoonshot